NSCLC Connect
  • Saved
Apigenin Enhanced Antitumor Effect of Cisplatin in Lung Cancer via Inhibition of Cancer Stem Cells

Apigenin Enhanced Antitumor Effect of Cisplatin in Lung Cancer via Inhibition of Cancer Stem Cells

Source : https://oncologynation.com/journal/61974

Oncology Nation is the leading online medical community exclusively for Oncologists and Hematologists enabling specialized consultation, communication, and information exchange within a private and secure platform.


API was found to eliminate acquired CDDP resistance and decrease the proportion of CSCs in a p53-dependent manner in NSCLC. An API-induced decrease in the CSC population could contribute to enhance the antitumor effect of CDDP via p53 (Figure 4D). Thus, API might be a good candidate for NSCLC therapy, especially when combined with CDDP.

  • Saved


Intrapleural treatment in patients with non-small cell lung cancer with malignant pleural effusions in the real world - PubMed

Intrapleural treatment in patients with non-small cell lung cancer with malignant pleural effusions in the real world - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34741494/

doi: 10.1111/1759-7714.14224. Online ahead of print. 1 Department of Pulmonary and Critical Care Medicine, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China. 2 Department of Pulmonary and Critical...

  • 4yr
    Key Points • Source: Thoracic Cancer • Conclusion/Relevance: “Intrapleural treatment can prolong the survival of NSCLC patients with MPE (malignant pleural effusions) who do not receive targeted treatment or who only receive Show More
  • Saved


The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with RET alterations - PubMed

The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with RET alterations - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34726500/

BACKGROUND: Lung cancer is the leading cause of cancer death in the United States. Non-small cell lung cancer (NSCLC) accounts for 80% to 85% of all lung cancers. Thyroid cancer,...

  • Saved


Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy - PubMed

Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34661758/

1 State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Taipa, 999078, Macao SAR, China. 2 Department of Pharmaceutical Science, University of...

  • Saved


Outcomes With Local Therapy and Tyrosine Kinase Inhibition in Patients With ALK/ROS1/RET-Rearranged Lung Cancers - PubMed

Outcomes With Local Therapy and Tyrosine Kinase Inhibition in Patients With ALK/ROS1/RET-Rearranged Lung Cancers - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34701454/

1 Memorial Sloan Kettering Cancer Center, New York, NY. 2 Memorial Sloan Kettering Cancer Center, New York City, NY. 3 Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New...